LOS ANGELES , Nov. 13, 2024 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on high-purity, pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today announced financial results for its third quarter ended September 30, 2024 , and provided a corporate update.
Third Quarter 2024 and Recent Developments: Completed enrollment of the Phase 2 study ("Tail wind ") of inhaled AP-PA02 in patients with non-cystic fibrosis bronchiectasis ("NCFB") and chronic pulmonary Pseudomonas aeruginosa ( "P. aeruginosa" ) infection. Topline data expected by year-end.
Working towards initiating a pivotal bronchiectasis trial in 2025 for chronic pulmonary P. aeruginosa infection. Completed enrollment of Phase 1b /2a study ("diSArm") of intravenous AP-SA02 in patients with Staphylococcus aureus ( "S.
aureus" ) bacteremia. Topline data expected in the first quarter of 2025. Moving towards initiating a pivotal S.
aureus bacteremia trial in 2025. Received $5.25 million of additional non-dilutive funding to support the diSArm study pursuant to a previously announced Department of Defense grant, received through the Medical Technology Enterprise Consortium ("MTEC") and managed by the Naval Medical Research Command (NMRC) – Naval Advanced Medical Development (NAMD) with funding from the Defense Health Agency and Joint Warfighter Medical Research Program.
Further a.
